Xgeva Matches Standard of Care in Delaying Bone Lesions in Multiple Myeloma Patients, Amgen Reports
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met its primary endpoint in a  Phase 3 trial as a potential treatment for bone complications in…